Table 2.
Recipient characteristics
| Characteristics | Value |
|---|---|
| Age, mean ± SD; median (min–max) | 49.4 ± 13.2; 51 (18–79) |
| Race, n (%) | |
| White | 1472 (67.7) |
| African American | 337 (15.5) |
| Other | 365 (16.8) |
| Ethnicity, n (%) | |
| Hispanic | 194 (8.9) |
| Non-Hispanic | 1980 (91.1) |
| Sex, n (%) | |
| Female | 883 (40.6) |
| Male | 1291 (59.4) |
| BMI, mean ± SD; median (min–max) | 27.9 ± 5.6; 27.5 (11.3–52.1) |
| Retransplants, n (%) | 319 (14.7) |
| Pre-emptive, n (%) | 486 (22.4) |
| Waiting time (on list), mean ± SD; median (min–max) | 656.8 ± 597.5; 485 (0–4941) |
| Most recent peak PRA, n (%) | |
| ≤20 | 2060 (94.8) |
| 21–80 | 80 (3.7) |
| >80 | 34 (1.6) |
| DM, n (%) | 597 (27.5) |
| PVD, n (%) | 110 (5.1) |
| Cause of ESKD, n (%) | |
| DM | 457 (21.0) |
| HTN | 342 (15.7) |
| PKD | 298 (13.7) |
| FSGS | 151 (6.9) |
| IgA | 122 (5.6) |
| Others | 804 (37.0) |
BMI, body mass index; DM, diabetes mellitus; ESKD, end-stage kidney disease; FSGS, focal segmental glomerular sclerosis; HTN, hypertension; max, maximum; min, minimum; PKD, polycystic kidney disease; PRA, panel reactive antibody.